GlassScriptPhysician profile
James Bernheimer
NPI 1740227073
$8,082.82
in general payments reported to CMS, 2019-2025
39 companies · $2,124 in 2025
The $2,124 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $85.97 · 2021: $127 · 2022: $1,070 · 2023: $2,016 · 2024: $1,892 · 2025: $2,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,032.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $1,133.28 | 2021-2023 | Uplizna |
| Abbvie INC. | $1,044.08 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Amgen INC. | $828.60 | 2024-2025 | Uplizna |
| Ucb, INC. | $426.67 | 2019-2025 | Rystiggo, Zilbrysq, Nayzilam |
| Alexion Pharmaceuticals, INC. | $365.57 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $338.94 | 2019-2025 | |
| Neurelis, INC. | $335.33 | 2022-2025 | Valtoco |
| Sk Life Science, INC. | $326.76 | 2022-2025 | |
| Pfizer INC. | $317.48 | 2023-2025 | |
| Lilly USA, LLC | $306.66 | 2019-2024 | Emgality, Kisunla, Amyvid |
| Genzyme Corporation | $280.46 | 2019-2025 | |
| Celgene Corporation | $264.70 | 2023-2025 | Zeposia |
| Eisai INC. | $263.18 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $245.33 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $230.00 | 2024-2025 | Zeposia |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $229.41 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $180.03 | 2023-2025 | Vumerity, Tysabri, Avonex |
| Genentech USA, INC. | $87.46 | 2023-2024 | Ocrevus |
| Grifols USA, LLC | $77.54 | 2024-2025 | Gamunex-C |
| Sumitomo Pharma America, INC. | $73.77 | 2023-2024 | Aptiom |
| Emd Serono, INC. | $72.92 | 2019-2023 | Mavenclad |
| Tanabe Pharma America, INC. | $70.64 | 2023-2025 | Radicava |
| Lundbeck LLC | $63.29 | 2023-2025 | Vyepti |
| Supernus Pharmaceuticals, INC. | $61.38 | 2019 | |
| Ceribell, INC. | $59.25 | 2025 | Pocket Eeg Device |
| Csl Behring | $53.34 | 2024-2025 | Hizentra |
| Acadia Pharmaceuticals INC | $42.75 | 2019 | |
| Janssen Biotech, INC. | $38.41 | 2025 | |
| Medtronic, INC. | $35.29 | 2025 | Aquamantys(Tm) |
| Astrazeneca Pharmaceuticals LP | $34.49 | 2019-2025 | Wainua |
| Axsome Therapeutics, INC. | $31.74 | 2025 | Symbravo |
| Neurocrine Biosciences, INC. | $28.68 | 2024 | Ingrezza |
| Tg Therapeutics, INC. | $25.44 | 2023 | |
| Livanova USA, INC. | $23.38 | 2022 | |
| Merz Pharmaceuticals, LLC | $20.97 | 2025 | Inbrija |
| Allergan, INC. | $18.29 | 2019 | |
| Amarin Pharma, INC. | $17.75 | 2019 | |
| Vanda Pharmaceuticals INC. | $15.56 | 2025 | Ponvory |
| Collegium Pharmaceutical, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bernheimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.